- Home
- ACT vs LEGN Comparison
ACT vs LEGN Comparison
Compare ACT & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACT
- LEGN
- Stock Information
- Founded
- ACT 1981
- LEGN 2014
- Country
- ACT United States
- LEGN United States
- Employees
- ACT N/A
- LEGN N/A
- Industry
- ACT Specialty Insurers
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- ACT Finance
- LEGN Health Care
- Exchange
- ACT Nasdaq
- LEGN Nasdaq
- Market Cap
- ACT 5.1B
- LEGN 5.4B
- IPO Year
- ACT 2021
- LEGN 2020
- Fundamental
- Price
- ACT $36.28
- LEGN $34.00
- Analyst Decision
- ACT Buy
- LEGN Strong Buy
- Analyst Count
- ACT 4
- LEGN 12
- Target Price
- ACT $37.75
- LEGN $77.09
- AVG Volume (30 Days)
- ACT 412.8K
- LEGN 2.0M
- Earning Date
- ACT 07-30-2025
- LEGN 08-08-2025
- Dividend Yield
- ACT 2.32%
- LEGN N/A
- EPS Growth
- ACT 9.98
- LEGN N/A
- EPS
- ACT 4.44
- LEGN N/A
- Revenue
- ACT $1,216,974,000.00
- LEGN $728,303,000.00
- Revenue This Year
- ACT $4.51
- LEGN $65.49
- Revenue Next Year
- ACT $4.46
- LEGN $53.76
- P/E Ratio
- ACT $8.16
- LEGN N/A
- Revenue Growth
- ACT 4.52
- LEGN 112.46
- 52 Week Low
- ACT $29.97
- LEGN $27.34
- 52 Week High
- ACT $37.56
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- ACT 58.24
- LEGN 53.16
- Support Level
- ACT $34.77
- LEGN $33.84
- Resistance Level
- ACT $36.40
- LEGN $35.29
- Average True Range (ATR)
- ACT 0.70
- LEGN 1.96
- MACD
- ACT 0.14
- LEGN 0.24
- Stochastic Oscillator
- ACT 95.10
- LEGN 52.16
About ACT Enact Holdings Inc.
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The principal mortgage insurance customers are originators of residential mortgage loans who determine which mortgage insurer or insurers will be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.